Equities

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS

ONCSM.E:IST

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS

Actions
Health CareMedical Equipment and Services
  • Price (TRY)94.50
  • Today's Change-1.95 / -2.02%
  • Shares traded404.15k
  • 1 Year change-39.77%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 15:09 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS is a Turkey-based company, which is engaged in the production of medical devices. The Company manufactures electromedical and electrotherapeutic apparatus, surgical and medical instruments, and other related medical products. Oncosem Onkolojik Sistemler is specialized in the manufacturing of equipment and medical devices used in cancer treatment, and it offers fully automated chemotherapy drug preparation devices, diagnostic tests and protective equipment, and waste collection devices. The Company also manufactures hazardous waste sealing systems, chemotherapy preparation and administration consumables, Oncosem devices' components, and infusion pumps.

  • Revenue in TRY (TTM)310.86m
  • Net income in TRY-133.70m
  • Incorporated2008
  • Employees249.00
  • Location
    Oncosem Onkolojik Sistemler Sanayi ve Ticaret ASMutlukent Mh. 1988 Cd. No: 12 CankayaANKARA 06510TurkeyTUR
  • Websitehttps://oncosem.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
AbL Diagnostics SA204.81m1.98m1.67bn19.00842.736.7663.878.150.00340.00340.34830.420.3703--1.42295,411.600.35873.240.58844.43----0.96858.811.87-47.510.3389---35.8474.86-95.08-49.30----
Medicalgorithmics SA293.80m-85.35m1.82bn120.00--2.60--6.19-1.02-1.023.528.390.30480.67188.57291,900.00-8.85-0.9441-9.71-1.1880.0889.46-29.05-2.191.65--0.05130.00-31.28-26.39-102.27---18.81--
Omda AS1.31bn-80.70m1.87bn271.00--9.5121.161.43-1.27-1.2720.923.030.584737.9313.471,447,038.00-3.83-4.92-7.72-6.3793.0790.22-6.55-9.831.150.06810.8875--12.3019.83179.30---3.93--
Carmat SA201.75m-1.95bn1.93bn162.00------9.59-1.76-1.760.1787-0.64190.09321.611.2830,379.12-89.92-76.92-113.71-94.38-535.50---964.91-4,636.641.69-17.371.63--710.72---0.3502--16.99--
Tissue Regenix Group PLC1.09bn-37.82m1.96bn76.00--1.901,499.081.79-0.0123-0.01230.35360.33010.70611.336.41328,220.30-2.17-13.45-2.43-14.7849.4845.90-3.08-28.801.470.37160.263--20.5013.7536.44--9.78--
Mentice AB865.34m-73.38m2.02bn130.00--4.63205.962.34-0.9104-0.910410.715.420.92432.774.382,250,394.00-7.84-7.69-15.21-13.0785.8983.67-8.48-10.000.9251--0.0285--25.5411.7490.81---10.83--
Gentian Diagnostics ASA455.85m6.89m2.09bn58.00345.404.1659.274.580.12620.12629.3510.470.77921.698.402,533,190.001.18-10.761.33-11.8651.6941.461.51-26.995.01--0.0394--32.9827.6354.92---4.92--
Senzime AB (publ)174.28m-414.35m2.18bn52.00--2.56--12.50-1.09-1.090.45952.380.15331.574.91---36.44-35.69-39.12-38.0033.27-20.59-237.75-558.682.62--0.0739--154.7761.90-1.09---3.69--
OssDsign AB389.13m-358.69m2.22bn27.00--3.13--5.70-1.40-1.401.432.300.43112.506.802,572,083.00-39.74-37.92-43.39-43.5683.9468.10-92.18-203.065.92-21.650.0114--96.8453.26-31.30---56.16--
Oncosem Onkolojik Sistemlr Sny v Tcrt AS310.86m-133.70m2.30bn249.00--9.83--7.40-5.70-5.7013.129.811.023.664.56959,448.30-43.70---61.60--21.29---43.01--1.10-5.210.2552---17.90---284.37------
ADDvise Group AB (publ)5.13bn360.57m2.42bn643.0020.223.053.650.47240.59350.59358.383.930.5658.375.772,606,250.003.983.724.824.7742.0748.957.045.891.402.350.69690.940544.3038.6227.62--30.35--
Affluent Medical SAS0.00-621.83m2.53bn66.00--2.24-----0.5338-0.53380.000.78640.00----0.00-28.43---34.69-------------24.620.3586-------2.80------
Fonet Bilgi Teknolojileri AS392.86m188.95m2.58bn498.005.972.848.146.573.003.003.326.320.5937375.463.92898,996.6028.5515.8532.4418.1627.2435.8448.1036.801.72--0.00620.005.3647.56520.6464.7949.71--
Median Technologies SA796.76m-925.06m2.72bn250.00------3.42-1.29-1.291.11-1.190.7873-30.313.5790,227.27-91.41-54.57---157.51105.00101.57-116.10-93.700.6879-138.584.77---6.1028.52-13.70--38.38--
Inspecs Group PLC8.54bn-179.83m2.74bn1.67k--0.61347.350.3204-0.0404-0.04041.921.000.86672.317.65116,640.80-1.82-1.48-2.62-2.1551.4648.50-2.10-1.970.86960.64410.377--1.1636.4584.22--51.04--
SDI Group PLC2.88bn185.26m2.77bn503.0015.051.397.680.96060.04020.04020.62560.43440.7930.9895.34130,906.605.127.856.1110.0130.8464.066.469.481.354.850.3210.00-2.5630.469.3017.2212.08--
Data as of Nov 13 2024. Currency figures normalised to Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS's reporting currency: Turkish Lira TRY
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.